Spark Therapeutics, Inc. (NASDAQ:ONCE) has received an average rating of “Buy” from the twenty-two brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eighteen have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $90.47.

A number of brokerages have weighed in on ONCE. Jefferies Group LLC restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. SunTrust Banks, Inc. restated a “buy” rating and set a $95.00 price objective (up previously from $85.00) on shares of Spark Therapeutics in a research note on Monday, September 25th. Cowen and Company restated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Cantor Fitzgerald set a $94.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday, October 6th.

Spark Therapeutics (NASDAQ ONCE) traded up 1.34% during trading on Friday, reaching $81.87. The company’s stock had a trading volume of 483,213 shares. The company’s market capitalization is $2.99 billion. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $91.75. The company’s 50-day moving average is $85.32 and its 200-day moving average is $85.32.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. During the same quarter last year, the business posted ($1.04) EPS. Spark Therapeutics’s quarterly revenue was up 14.7% compared to the same quarter last year. Equities analysts anticipate that Spark Therapeutics will post ($7.59) EPS for the current year.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/22/spark-therapeutics-inc-once-given-consensus-recommendation-of-buy-by-analysts.html.

In other Spark Therapeutics news, insider Katherine A. High sold 10,000 shares of Spark Therapeutics stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $72.53, for a total transaction of $725,300.00. Following the sale, the insider now owns 220,000 shares of the company’s stock, valued at approximately $15,956,600. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 28,650 shares of Spark Therapeutics stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $80.01, for a total value of $2,292,286.50. Following the sale, the chief executive officer now directly owns 258,650 shares in the company, valued at approximately $20,694,586.50. The disclosure for this sale can be found here. Insiders have sold a total of 1,333,195 shares of company stock worth $109,070,506 in the last ninety days. 7.30% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its position in shares of Spark Therapeutics by 11,332.0% during the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after purchasing an additional 1,824,117 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Spark Therapeutics during the 2nd quarter valued at $30,848,000. Sectoral Asset Management Inc acquired a new position in shares of Spark Therapeutics during the 2nd quarter valued at $6,052,000. Vanguard Group Inc. increased its position in shares of Spark Therapeutics by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after purchasing an additional 96,803 shares during the period. Finally, Janus Capital Management LLC increased its position in shares of Spark Therapeutics by 21.4% during the 1st quarter. Janus Capital Management LLC now owns 458,743 shares of the biotechnology company’s stock valued at $24,468,000 after purchasing an additional 80,750 shares during the period. 77.84% of the stock is currently owned by hedge funds and other institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.